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Advances in the field of T cell immunology have contributed to the understanding that cross-reactivity is an intrinsic
characteristic of the T cell receptor (TCR), and that each TCR can potentially interact with many different T cell epitopes.
To better define the potential for TCR cross-reactivity between epitopes derived from the human genome, the human
microbiome, and human pathogens, we developed a new immunoinformatics tool, JanusMatrix, that represents an
extension of the validated T cell epitope mapping tool, EpiMatrix. Initial explorations, summarized in this synopsis, have
uncovered what appear to be important differences in the TCR cross-reactivity of selected regulatory and effector T cell
epitopes with other epitopes in the human genome, human microbiome, and selected human pathogens. In addition to
exploring the T cell epitope relationships between human self, commensal and pathogen, JanusMatrix may also be useful
to explore some aspects of heterologous immunity and to examine T cell epitope relatedness between pathogens to
which humans are exposed (Dengue serotypes, or HCV and Influenza, for example). In Hand-Foot-Mouth disease (HFMD)
for example, extensive enterovirus and human microbiome cross-reactivity (and limited cross-reactivity with the human
genome) seemingly predicts immunodominance. In contrast, more extensive cross-reactivity with proteins contained
in the human genome as compared to the human microbiome was observed for selected Treg epitopes. While it may
be impossible to predict all immune response influences, the availability of sequence data from the human genome,
the human microbiome, and an array of human pathogens and vaccines has made computationally–driven exploration
of the effects of T cell epitope cross-reactivity now possible. This is the first description of JanusMatrix, an algorithm
that assesses TCR cross-reactivity that may contribute to a means of predicting the phenotype of T cells responding to
selected T cell epitopes. Whether used for explorations of T cell phenotype or for evaluating cross-conservation between
related viral strains at the TCR face of viral epitopes, further JanusMatrix studies may contribute to developing safer, more
effective vaccines.

Introduction
JanusMatrix is a new immunoinformatics tool that was developed
to compare T cell epitope conservation between protein sequences
from bacterial and viral organisms that make up the human gut
microbiome (HM), autologous proteins from the human genome
(HG), and human viral and bacterial pathogens (HP). We have
used JanusMatrix to initiate the exploration of the relationships
between conservation with self (and non-self), T cell phenotype
(regulatory or effector), and immunodominance. For example,
we postulated that regulatory T cells (Treg) might bear T cell
receptors (TCRs) that are more likely to bind to T cell epitopes
that are cross-conserved (at the TCR face) in many human (self)
proteins, while, by comparison true effector T cells (Teff) might
bear TCRs that recognize TCR-facing residues that are less crossconserved with human genome proteins. We reasoned that such

cross-conserved epitopes might be important to remove from vaccines, because of the potential for cross-reactive T cells to the vaccine epitopes to suppress, or alter, the desired immune response.
The tool may also be used to uncover pathogen epitopes that
are associated with autoimmune responses, and epitopes that are
conserved between two similar pathogens (Dengue serotypes) or
slightly dissimilar pathogens (West Nile Virus and Yellow Fever
Virus, for example). The purpose of this review is to describe
the use of this tool, as it is currently being implemented in our
research programs, and to illustrate several potential applications
of JanusMatrix to vaccine research and development.
The mechanics of T cell receptor cross-reactivity. T cells recognize linear peptides or “T cell epitopes” that form a complex
with human (HLA) or other species’ MHC molecules. The T cell
bears a surface receptor (T cell receptor, or TCR) that binds to
the T cell epitope’s amino acid side chains facing upwards, out of
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Figure 1. JanusMatrix separates the amino acid sequence of T cell epitopes into TCR-facing residues and HLA binding cleft-facing residues,
and then compares the TCR face to other putative T cell epitopes.
JanusMatrix defines cross-reactive T cell epitopes as those that have the
same MHC allele restriction, the same or similar T cell-facing residues
(epitope), and conserved binding of MHC-facing residues (agretope).
The HLA-facing residues of the comparators are allowed to vary, as long
as they still bind to the original HLA allele. Epitopes that are identical
in terms of their TCR face and are equally able to bind to the identical
HLA, but differ in sequence, are rapidly identified from a given database
of genomic sequences. This enables large-scale comparisons between
TCR-homologous T cell epitopes from the HG, the HM, and the HP.

the MHC binding cleft, while the MHC binds to the T cell epitope’s amino acid side chains facing into “pockets” located on the
sides and bottom of the binding cleft. The T cell epitope face that
binds into the MHC-binding cleft is known as the “agretope”,
while “epitope” refers to either the whole linear peptide or to the
TCR face of the peptide (Fig. 1).
Effective T cell immunity requires that the host be able to
generate a specific response to antigenic epitopes without any
prior knowledge of their composition. In this regard, the immune
system faces a fundamental dilemma: how to cover the vastly
higher number of potential epitopes (estimated at > 1012) with
available TCRs (estimated maximum of < 108 in humans). One
hypothesis for resolving this dilemma is that TCRs may recognize more than one peptide epitope. This theory has since been
validated: indeed, each TCR has the potential to recognize as
many as one million peptides. The possibility for cross-reactivity
may seem high and even potentially dangerous, but given the
number of potential T cell epitopes represented by modifying
the 20 amino acids at each of the TCR-facing positions, it turns
out that this reflects a minimum cross-specificity of 1:100,000
peptides.1 Thus, there is a relatively limited probability of crossreactivity with self as well as foreign antigens. While it is true

that altering MHC binding residues can modify the affinity of
the peptide and change the shape of the TCR face, the TCR has
been shown to adapt to minor changes, enabling a single TCR to
bind to more than one epitope containing the same TCR-facing
but different MHC-binding-facing residues.2,3
Rules of contact enable the generation of TCR crossreactivity predictions. Based on crystal structures of ternary
MHC:peptide:TCR structures, general patterns of contact have
been observed, with some peptide residues frequently in contact
with the MHC and others frequently in contact with the TCR.4
These TCR-facing and MHC-facing amino acid residue rules
can be adapted for use with T cell epitope prediction tools such
as EpiMatrix5 to define cross-conserved TCR-facing residues
across large sequence databases (see JanusMatrix algorithm,
below). Once a single T cell epitope is defined, by holding its
TCR-facing residues constant and allowing its MHC-binding
residues to vary, it becomes possible to search protein sequence
databases for epitopes that appear “homologous” to a given
TCR, despite minor variations in MHC binding residues, that
will still be predicted to bind to the same MHC. As a first
approximation, this approach reduces the number of potential cross-reactive sequences identified and makes experimental
validation feasible. In reality, however, TCRs are not required
to recognize HLA-bound peptides by sequence similarity but
rather by peptide side chain accessibility.6,7 Consequently, the
set of potential cross-reactive sequences is very likely dramatically greater and would be unwieldy in initial validation experiments. We believe experimental confirmation in the simplest
case (identical TCR-facing residues) is a reasonable first step
to be followed by computational screening of an expanded
sequence/structure space to capture additional cross-reactive
epitopes.
TCR cross-reactivity between self and non-self. Crossreactivity is an intrinsic characteristic of the TCR, i.e., each single TCR can potentially interact with different peptide-MHC
complexes. In fact, T cell epitope cross-reactivity is critical to
many aspects of T cell biology, including positive and negative
selection. Cross-reactive immunity can have either advantageous
or negative (e.g., leading to pathology) consequences. Deleterious
autoimmune cross-reactivity can occur following infection, a
response that has previously been described as molecular mimicry. For example, T cell epitope cross-reactive immune responses
may contribute to the pathogenesis of systemic lupus erythematosus,8 tropical spastic paraparesis,9 and diabetes,10 among other
conditions. While we have not yet used JanusMatrix to define
cross-reactivity between human pathogens and T cell epitopes
associated with auto-immune disease, this is an area of great
interest that we are likely to pursue in the future.
Heterologous immunity: TCR cross-reactivity between
pathogens. Heterologous immunity is a term coined by Welsh
and Selin to describe the partial immunity (or altered immunopathology) that occurs in response to a pathogen if the host has
been previously infected or immunized with a particular unrelated pathogen. Both human and murine immune responses to
antigens can be modified as a consequence of T cell cross-reactivity.11-13 In some cases, heterologous immunity is attributed to
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T cells that cross-react with both pathogens. CD8 + T cell crossreactivity has been documented between two epitopes on the
same viral protein, between epitopes of different proteins from
the same virus and, more importantly, between epitopes of proteins from different viruses.14
Heterologous immunity research focused initially on specific
viral infections (e.g., vaccinia, EBV, influenza).15,16 It is now clear
that T cells stimulated by epitopes from a given pathogen may
subsequently respond differently to cross-reactive similar epitopes with later infection by a different virus.17 T cells that have
been previously activated due to a cross-reactive infection are
capable of restricting pathogen growth and reducing the severity
of the second infection, which can be viewed as a positive effect.
In the context of some infections caused by different viruses,
heterologous immunity may contribute to the immunodominance of low-avidity memory responses over higher-avidity naïve
responses. However, in other circumstances, the result of crossreactive immunity is enhanced pathogen growth and/or immunopathology.18 Proposed mechanisms underlying these negative
effects may include induction of Treg or, in contrast, increased
production of inflammatory cytokines.11,19-21 JanusMatrix is currently being used to search for epitopes that may contribute to
heterologous immunity.
The relevance of the HM to adaptive T cell responses.
Evidence linking gut microbes, adaptive immunity, metabolic
syndrome, allergy, and autoimmune disorders has emerged.22,23
For example, linkages between immune responses to the HM
and multiple sclerosis have been defined,23 as have links between
microbiota and autoimmune diseases of the gut.24,25 Exposure
to a diverse array of gut microbes may reduce susceptibility to
autoimmune diseases and allergy (the so-called “hygiene hypothesis”).22,23,26 This may be attributable to direct interactions
between the microbes and the human immune system (due to
not-yet-defined factors) or to modulation of immune responses
to self and other potential pathogens.24,27-29
In addition, there is a growing body of evidence that the gut
microbiome shapes adaptive immune responses.27,30,31 Notably,
post-thymic educated gut CD4 + T cells differentiate to become
inducible Treg by training on commensal antigens.32 This finding
is significant because it establishes the existence of T cells with
specificities for commensals, which may cross-react with pathogen- or vaccine-derived sequences. Since the gut microbiome is
both vast and highly variable, it is likely that commensal-shaped
immune responses are highly diverse and vary from person to
person due to individual variations in the microbiome (related
to diet or geography) and to genetic differences in HLA. In published33 and yet-to-be-published34 work, Sztein and VerBerkmoes
have established the uniqueness and commonalities between
individual microbial and human proteomes.
The availability of fast and accurate tools to analyze a large
number of sequences for common TCR-facing residues now
makes it both feasible and exciting to examine the role that crossreactive T cell epitopes play in the generation of autoimmune and
the modulation of adaptive immune responses. In the next section, we provide a brief description of the JanusMatrix tool and
its application to: (1) evaluations of common “positive control”

T cell epitopes for cross-reactivity between the HG and HM; (2)
understanding the pathogenesis of hepatitis C virus (HCV); and
(3) the discovery of T effector epitopes in EV71, the etiologic
agent of Hand-Foot-Mouth disease (HFMD). For these initial
studies, we applied JanusMatrix retrospectively to explore crossreactive patterns of previously studied epitopes that induced
various T cell responses, as well as prospectively to identify and
experimentally evaluate new cross-reactive epitopes predicted to
induce various responses.
Results
Developing epitope “silos”. Using EpiMatrix and JanusMatrix,
we mapped groups of peptides that were experimentally shown to
induce a defined T cell response (Teff, Treg, or no response) and
searched for trends in the number of cross-reactive TCR-facing
epitopes across the HG, HM, and HP databases supported by
JanusMatrix. A set of 10,000 random nine-mers was also evaluated for comparison.
Based on cross-reactivity patterns, T cell epitopes examined
thus far appear to fall into one of three categories, or “silos”: (1)
patterns that are characteristic of Treg epitopes; (2) patterns that
are characteristic of Teff epitopes; and (3) patterns associated
with epitopes that are “null” (neither effector nor regulatory but
are predicted to bind to HLA). We find these distinctive crossreactivity patterns are generally correlated with the types of T
cell epitopes defined in the literature. Specifically, T cell epitopes
that appeared to be immunodominant were associated with Treg
responses, as defined by upregulation of FoxP3 or expansion of
CD4 + CD25hi Treg, and had higher levels of cross-reactivity with
the HG.
Table 1 describes the emerging JanusMatrix patterns associated with T cell epitope categories (Treg, Teff) and provides an
example for each category (a defined Treg epitope for HCV35-37
and a defined Teff epitope in influenza 38) in terms of their TCR
cross-reactivity with the HG, HM, and selected human viral
and bacterial pathogens (HP). “CEFT” epitopes that are commonly used as positive controls in human T cell assays to elicit
a measurable antigen-specific memory response (see list of these
epitopes in ref. 39) and Tregitopes (see ref. 40) were tested as
representative sets of T effector and T regulatory epitopes respectively. Medians and ratios of cross-reactive hits are shown. We
also describe cross-reactivity that could be expected in a random protein: 10,000 random nine-mers predicted to be HLA
ligands show the lowest median of cross-reactive hits for each
database analyzed. Number of genomes, proteins, and amino
acids per database is also shown. Results of the statistical analysis
(P-values) of the comparison between the distributions of ratios
of cross-reactive hits between databases and types of epitopes are
also shown in sub-tables. Comparisons between type of epitopes
by database (e.g. CEFT vs. Treg for HG; see sub-table A) show
that (1) Treg and CEFT are only different for HG; and (2) for
the three databases, CEFT and Tregs are different from random;
the only exception is the comparison of HP CEFT vs. Random.
Comparisons between databases by type of epitope (e.g. HG vs.
HM for CEFT; see sub-table B) we observe that (1) for CEFT,
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Table 1. JanusMatrix TCR-cross reactivity frequencies for three types of epitopes
Median cross-reactive hits (Ratio, 1 x 106)a
Database

T eff epitopes

Treg epitopes

Random

CEFT

Influenza A

Tregs

HCV

Self
(HG)

2 (0.18)

0 (0.00)

8.5 (0.75)

23.5 (2.08)

Microbiome
(HM)

29 (0.13)

38 (0.17)

31 (0.14)

Pathogens
(HP)

17 (0.12)

11 (0.08)

19 (0.13)

Per database, number of
Genomes

Proteins

Amino acids

1 (0.09)

1

20,248

11,301,336

103 (0.47)

14 (0.06)

204

705,684

218,452,796

107.5 (0.73)

10 (0.07)

221

455,237

146,398,849

A
Epitope type

HG

HM

HP

Treg vs. CEFT

<0.05

0.63

0.62

CEFT vs. Random

<0.05

0.05

0.11

Treg vs. Random

<0.05

<0.05

<0.05

Database

CEFT

Treg

Random

HG vs. HM

0.10

<0.05

<0.05

HG vs. HP

0.24

<0.05

<0.05

HM vs. HP

0.50

0.15

<0.05

B

Ratio of cross-reactive hits per number of amino acids in the comparison database. bNine-mer predicted to be an epitope. (A) P-values of comparisons
between ratios across three types of epitopes by database. (B) P-value of comparisons between ratios across databases by type of epitope. Median of
cross-reactive hits for T effector epitopes, T regulatory epitopes, and Random 9-mers are shown. CEFT and Tregs are tested as representative sets of T
effector and T regulatory epitopes. Examples for both categories are also included; a defined Teff epitope in influenza A and a Treg epitope for HCV. TCR
cross-reactivity with HG, HM, and selected human viral and bacterial pathogens (HP) was evaluated. Ratios of cross-reactive hits by number of amino
acids in the comparison database are shown in parenthesis. Number of genomes, proteins, and amino acids per database is also shown. Analyses were
preformed with a 95% confidence level.

a

the distributions of the ratios of cross-reactive hits of the three
databases are not different; (2) for Tregs, HG is different from
both HM and HP and HM is not different from HP; and (3) for
random peptides, HG, HM, and HP are all different.
In summary, these results indicate that validated Treg epitopes have statistically greater TCR cross-reactivity with the
human genome, based on JanusMatrix. Teff and Treg crossreactivities with HG, HM, and HP are different from random
nine-mers (Teff vs. Random for HP is the exception). Teff distributions of the ratios of cross-reactive hits are not different
between databases. Some of the overlap between HP and HM
and HG might be due to co-opting of HG cross-reactivity by
human pathogens to escape immune response. Cytoscape-based
TCR-epitope network patterns for the HCV Treg epitope and
influenza Teff epitope are shown in Figure 2.
Illustration of JanusMatrix patterns. Example 1. “Positive
control” T cell epitopes (Table 2). We had previously evaluated these 15 CEFT epitopes for MHC binding affinity, using
EpiMatrix and found that their reported MHC restriction was
highly correlated with EpiMatrix predictions, and that most
epitopes were also predicted to bind to a number of additional
MHC class II alleles with high affinity.39 Although the median
number of cross-reactive hits between these T cell epitopes and
the HM (Median = 29, SD = 68.03) is different from the median
number of hits with the HG (Median = 2, SD = 5.96), no significant difference is found when the ratios of cross-reactive hits

are compared (p = 0.1; Table 1). However, the HLA allele for
which the predicted nine-mer ligand with the highest number
of cross-reactive hits with HG, HM, and HP is not the same
allele for which immunogenic response to CEFT 09 is reported.
This may suggest that the peptide contained within the larger
epitope induces a null (tolerant) or Treg response for individuals
possessing the predicted cross-reactive HLA.
Example 2. Viral HP. We recently mapped T cell epitopes for
EV71, the enterovirus that has been responsible for several outbreaks of HFMD in Asia.41 We found that extensive cross-reactivity with HM seemed to be associated with immunodominance
(Fig. 3). Shown in the figure are the T cell epitopes that were
tested in HFMD patients. One of the two immunodominant
epitopes (NTAYIIALAAAQKNFTMKL) was highly crossconserved with enteroviruses such as polio virus (not shown)
and with the human microbiome and pathogen sequences
(Fig. 3). As is described in greater detail in the original paper,
cross-reactivity between EV71 and poliovirus, appeared to be
linked to protection from severe HFMD and thus may be an
example of beneficial cross-reactive T cell responses.
Example 3. Human Treg epitopes from Hepatitis C. For a set of
Treg epitopes that were previously defined in HCV disease, HG
cross-reactivity appears to be much more extensive than HM.
Overall, greater cross-reactivity with HG seems to distinguish
published Treg and Teff epitopes from the same viral pathogen
(Fig. 4).
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Figure 2. TCR-Epitope Networks (developed using Cytoscape) for regulatory T cell epitopes (A) and effector T cell epitopes (B). Epitopes with TCRfacing residues similar to each of the test epitopes were identified in protein sequences from the human genome (HG; left), human microbiome (HM;
center), and human viral and bacterial genomes (HP; right) databases. Green diamonds represent source peptides; gray squares are predicted ninemer epitopes derived from the source peptide (predicted using EpiMatrix); blue triangles are nine-mers that are 100% identical to the TCR face of the
source epitope and that are predicted to bind to the identical HLA; and light purple circles are proteins containing the cross-reactive epitope.

Discussion
The future: two-faced epitopes. Using the newly developed
algorithm JanusMatrix, we have begun to expand the information available on the role of T cell epitopes conserved between
the HM, HG, and HP, and to understand how these epitopes
may influence the immune response. We are applying the tool
to examine whether exposure to human commensals alters
subsequent T cell responses to common human pathogens and
to re-examine prevailing paradigms related to autoreactive T
cells. This approach, in which we define a T cell epitope based
on a well-established T cell epitope-mapping algorithm,42,43 is
significantly different from previous analyses.44 JanusMatrix
compares putative T cell epitopes and their TCR-facing residues across genome sequences rather than linear peptide
fragments.
JanusMatrix may enable the definition of microbial T cell epitopes that contribute to host-microbial homeostasis. As disruption
of microbial homeostasis may contribute to autoimmunity, and
other pathological processes, the availability of the JanusMatrix
tool could significantly advance the understanding of and treatment for autoimmune and other disorders. The extensive crossreactivity of TCR-facing residues across genomic sequences and
the distinct patterns of cross-reactivity associated with T cell phenotype may have important implications for the development of
vaccines and for vaccine safety and efficacy, as T cells activated
by cross-reactive HM epitopes can exhibit differential ability(ies)
to respond to vaccine antigens.
Cross-reactive T cells such as those described for HFMD and
other enteroviruses may enhance immune responses following

exposure to a new pathogen or to a vaccine containing the
conserved T cell epitope. In contrast, cross-reactivity between
pathogens (or commensals) might redirect the immune response
towards suboptimal epitopes or enhance cytokine responses to
vaccine antigens, contributing to vaccine-related adverse events.
T cells activated by vaccination can also have cross-reactivity
with self-antigens.45,46 This can lead to the breakdown of tolerance mechanisms and subsequent autoimmune reactions.
Autoimmune reactions such as myocarditis, Guillain-Barré
syndrome, and vasculitis have been described after administration of several vaccines,47-52 but their cause is not fully understood. The JanusMatrix tool may be particularly valuable for
future explorations of immune-mediated adverse responses to
vaccination.
JanusMatrix may also be useful for defining homologous T cell
epitopes among variant strains or serotypes of the same pathogen.
For example, use of these defined rules to search for conserved
TCR-facing residues in large Dengue sequence databases may
contribute to understanding the immunopathogenesis of Dengue
Hemmorhagic Fever, a severe manifestation of Dengue infection.
In addition, the use of the tool may uncover important similarities between HIV and the human genome, that have long been
surmised but not yet validated.
Aspects of JanusMatrix analysis that may lead to inaccurate predictions. The current analysis relies on the accuracy
of the EpiMatrix epitope prediction tool, as well as the careful curation of protein sequences in each of the analyzed databases. While each of these sources is most certainly subject to
some error, the large deviations in the frequencies (see Table 1)
that we are observing seem to suggest that cross-reactivity at the
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Table 2. JanusMatrix analysis of the CEFT peptide pool
Number of cross-reactive hits
Source

Reported allele

Peptide sequence

Nine-mer

Alleles

HG

HM

HP

CEFT 01

DR4

FVFTLTVPSER

FVFTLTVPS

6

4

29

54

VFTLTVPSE

1

0

8

6

FTLTVPSER

4

6

31

40

CEFT 02

DR1

SGPLKAEIAQRLEDV

LKAEIAQRL

4

5

65

43

CEFT 03

DR1

YDVPDYASLRSLVASS

YASLRSLVA

7

7

49

68

CEFT 04

DR1

PYYTGEHAKAIGN

YTGEHAKAI

3

0

5

6

CEFT 05

DR3

GQIGNDPNRDIL

IGNDPNRDI

1

0

1

0

CEFT 06/07

DR1, DR4

PKYVKQNTLKLAT

CEFT 09

DR15

AGLTLSLLVICSYLFISRG

YVKQNTLKL

8

5

180

96

VKQNTLKLA

2

2

23

18

AGLTLSLLV

1*

33

336

364

TLSLLVICS

1

2

18

11

LLVICSYLF

5

0

14

7

VICSYLFIS

1

1

3

2

ICSYLFISR

1

2

17

2

CEFT 10/11

DR8, DR11, DR13, DR15

QYIKANSKFIGITEL

YIKANSKFI

8

2

104

76

IKANSKFIG

5

4

102

64

CEFT 12

DR7, DR11

FNNFTVSFWLRVPKVSASHLE

FNNFTVSFW

1

0

2

2

FTVSFWLRV

2

2

8

14

FWLRVPKVS

4

0

5

3

WLRVPKVSA

4

5

64

44

LRVPKVSAS

2

2

30

12

LYNLRRGTA

4

0

39

9

YNLRRGTAL

5

4

31

34

CEFT 13

CEFT 15

CEFT 17

CEFT 19

CEFT 22

CEFT 23

DR1

DR11

DR8

DR3

DR4

DR7

TSLYNLRRGTALA

VSIDKFRIFCKALNPK

DKREMWMACIKELH

KELKRQYEKKLRQ

AEGLRALLARSHVER

PGPLRESIVCYFMVFLQTHI

VSIDKFRIF

1

0

12

9

FRIFCKALN

4

6

25

23

MWMACIKEL

1

0

0

1

WMACIKELH

1

1

47

17

LKRQYEKKL

5

3

67

17

KRQYEKKLR

2

5

71

33

LRALLARSH

5

12

167

220

LLARSHVER

2

3

41

43

LRESIVCYF

1

0

6

2

YFMVFLQTH

1

0

4

1

*Immunogenicity for this peptide is not reported for the predicted allele (DR7), suggesting that the nine-mer peptide contained within the larger
epitope may induce a null (tolerant) or Treg response for individuals possessing this HLA.

TCR level may indeed influence T cell phenotype. We also note
that the sheer volume of genomic data that is available in the HP
and HM databases, compared to that of the HG may obscure
important pattern differences, and that redundancies in epitopes between pathogens may further obscure differences; future
iterations of this tool will allow a slight discount or ‘weighting’ of redundant epitopes. We also plan to normalize the comparisons of cross-reactive hits for each genome by defining the

median number of cross-reactive hits for 1 million random ninemer sequences. This would create a norm and standard deviations against which all other epitopes could be compared, and
also make it possible to report deviations from the norm for each
genome as a Z-score.
Population vs. individual specificity. We also note that the
JanusMatrix predictions are performed at the population-wide
level and are not based on any individual HLA type. Even if
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Figure 3. Hand-Foot-Mouth Disease (HFMD) epitope conservation in human microbiome/human pathogen genome sequence and immunodominance. The figure shows the potential importance of cross-reactivity between microbial genomes to the immunodominance of a particular epitope.
In HFMD, extensive cross-reactivity with the HM seems to predict immunodominance. Y axis: number of cross-reactive hits in the database; x axis,
individual epitopes (and nine-mers within those epitopes).

the general observation of the relationship between cross-reactivity and T cell phenotype holds true, these findings may vary
from individual to individual based on their HLA, their history
of exposures to vaccines and human pathogens, and their gut
microbiome.
Furthermore, it is likely that cross-reactive immune responses
are due to a diverse set of TCR-peptide-MHC interactions.
Rather than being defined by a single cross-reactive T cell
clone, it is likely that many different T cells, each with a unique
TCR, respond to cross-reactive epitopes. Each clonal TCR that
interacts with a set of peptide-MHC complexes (pMHC) may
respond with a different set of effector functions. Consequently,
specific patterns of cross-reactive immunity may occur only in
certain people due to individual variation in the pMHC-specific
T cell repertoire (“private specificity”).53 Nonetheless, detailed
understanding of these cross-reactive immune responses to prior
exposures, and the relatedness of these responses to HLA, may
lead to better vaccine designs and significant improvements in
vaccine efficacy.
The future. Due to advances in computational power, the
availability of vast genome sequences from commensals and
pathogens to which humans are exposed, and the development
of algorithms such as JanusMatrix, it is now possible to begin
exploring the HM-HG and HP-HG intersections at the level of
the T cell epitope. No comprehensive effort to uncover the conservation of HM epitopes across different pathogens and self proteins has been published to date, nor has the available literature
defined a set of generalizable principles underlying T cell crossreactivity that would permit predictions to be experimentally
tested in a prospective manner. We expect that the exploration of
the two-faced T cell epitope using JanusMatrix will significantly
advance human immunology in this respect.

Methods
JanusMatrix tool development. As implied by its name,a
JanusMatrix examines predicted T cell epitopes from both the
HLA-binding and TCR-facing perspectives, identifying as
potentially cross-reactive those that are predicted to bind the same
HLA (though perhaps with different amino acid composition on
the HLA-facing side) while presenting the same amino acids to
the TCR (Fig. 1). Given a starting protein sequence, putative T
cell epitopes are first identified using the EpiMatrix epitope-prediction tool. The JanusMatrix tool parses the epitopes into ninemer frames and divides each nine-mer into T cell receptor-facing
residues and MHC-binding residues, based on defined rules from
the literature.54 Specifically, for Class I: TCR facing residues are
considered to be residues 4, 5, 6, 7, 8, and for Class II: 2, 3,
5, 7, 8. JanusMatrix then searches for potentially cross-reactive
TCR-facing epitopes across any number of large sequence databases that have been pre-loaded into the tool, including the HM,
the HG, and HP. JanusMatrix focuses in 9-mer searches because
although peptides of different lengths interact with the MHC,
most T cell epitopes can be mapped to a minimum of nine or 10
amino acids in any given peptide, even if the peptide is longer.55,56
Future versions of the algorithm will include 10-mer as well as
9-mer searches.
Sequence databases. We have integrated available sequence
datasets into our JanusMatrix toolkit so as to uncover potentially
cross-reactive epitopes between self and microbes, including
the HG,57 HM,58 and bacterial59 and viral 60 proteomes that we
have compiled into one HP database.The number of genomes,
proteins, and amino acids per database was determined. In
addition, we have access to unpublished databases comprising
“frequently expressed proteins” of the HM, courtesy of Sztein
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Figure 4. Hepatitis C virus (HCV) epitope conservation in human microbiome/human pathogen genome sequence and immunodominance. For
regulatory T cell epitopes defined in HCV disease, HG cross-reactivity is more extensive. Overall, greater cross-reactivity with HG, HM, and HP seems
to distinguish published Treg and T effector epitopes. The exact parameters defining “greater” and “lesser” cross reactivity remain to be defined following the evaluation of a number of well-defined Treg and T effector epitope examples. Y axis: number of cross-reactive hits in the database; x axis,
individual epitopes (and nine-mers within those epitopes).

and VerBerkmoes (method described in ref. 24). The HM database of expressed peptide sequences was created from the most
extensive healthy human-microbial distal gut metaproteome
available to date.33 In order to obtain the metaproteome, cells
are enriched from fecal samples via differential centrifugation.
The samples are then enriched in microbial cells and thus had
a higher abundance of microbial proteins while still containing large amounts of interacting human proteins. The mixed
human-microbial proteome was lysed, denatured, and reduced
with 6 M Guanidine/10 mM DTT, and subsequently digested
into peptides with sequencing grade trypsin (Sigma). The complex peptide mixture was analyzed via shotgun proteomics on
a 2d-LC-MS/MS system (Linear Ion trap Orbitrap). The resultant MS/MS spectra were searched against a combined human
(human ref seq) and microbial isolates database (JGI-IMG HM
database). Proteins were computationally assembled from identified peptides (strictly filtered at ~1% false positive rate). The
entire dataset from both subjects was extracted for all identified
peptides and proteins and was provided as an annotated database
for upload into Janus Matrix.
Computational methods. JanusMatrix builds upon the
EpiMatrix epitope predictor, processing each genome to identify TCR-facing cross-conserved HLA-binding nine-mers.37,41,43
In addition to identifying cross-reactive epitopes and describing
these in tabular format, we have found it useful to visualize the
patterns with “epitope networks” using Cytoscape. An epitope
network has nodes for the epitopes and for the proteins that

contain them, with edges between cross-reactive pairs of epitopes
and between the proteins and their constituent epitopes. We have
incorporated Cytoscape61 into the JanusMatrix toolkit so as to
interactively visualize relatedness between selected T cell epitopes
and target genomes (HG, HM, HP) and to describe the resulting epitope networks. In the examples provided in Results, we
used JanusMatrix, EpiMatrix v1.2,62 and the genome databases
described above. Ratios of the cross-reactive hits per amino acids
in the comparison database (HG, HM, or HP) were calculated
for comparison purposes. Since the distributions of the ratios of
cross-reactive hits were not normally distributed, non-parametric
tests (Wilcoxon-Mann-Whitney test and Wilcoxon rank sum
test) were used to evaluate differences in the distributions of ratios
of cross-reactive hits between databases. Two type of comparisons
were performed: (1) Comparisons between ratios across types of
epitopes (Teff vs. Treg, Teff vs. Random, and Treg vs. Random)
by database, and (2) comparisons between ratios across databases
(HG vs. HM, HG vs. HP, and HM vs. HP) by type of epitope.
All the analyses were performed with a 95% confidence level.
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